TSXV - Delayed Quote CAD

BioSyent Inc. (RX.V)

11.75

+0.98

+(9.10%)

At close: May 16 at 3:54:28 PM EDT

BioSyent Releases Financial Results for First Quarter 2025

MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2025. Key highlights include: (CAD)Q1 2025% Change vs. Q1 2024Trailing Twelve Months (TTM) Mar 31, 2025% Change vs. TTM Mar 31, 2024Canadian Pharma Sales9,159,652+21%34,544,657+13%International Pharma Sales1,535,216n/a2,465,191+135%Legacy Business Sales284,092+52%1,266,373+15%Total Company Sales10,978,960+42%38,276,221+

GlobeNewswire yesterday

BIOYF
BioSyent Declares Second Quarter 2025 Dividend

MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on June 13, 2025, to shareholders of record at the close of business on May 30, 2025. This second quarter 2025 dividend compares with the first quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for

GlobeNewswire yesterday

BIOYF
Here's Why We Think BioSyent (CVE:RX) Is Well Worth Watching

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Simply Wall St. yesterday

BIOYF
BioSyent Schedules First Quarter Earnings Release for May 15, 2025

MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025 after market hours. A presentation on the Company’s first quarter 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “R

GlobeNewswire 8 days ago

BIOYF
BioSyent to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference

MISSISSAUGA, Ontario, April 30, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2025 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Monday, May 5th and Tuesday, May 6th, 2025. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent’s business and corporate activities

GlobeNewswire 16 days ago

BIOYF
Could The Market Be Wrong About BioSyent Inc. (CVE:RX) Given Its Attractive Financial Prospects?

It is hard to get excited after looking at BioSyent's (CVE:RX) recent performance, when its stock has declined 6.7...

Simply Wall St. 28 days ago

BIOYF
BioSyent to Attend Planet MicroCap Showcase

MISSISSAUGA, Ontario, April 14, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase: VEGAS 2025 investor conference in Las Vegas, Nevada from April 22nd to April 24th, 2025 at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, April 23rd from 12:30pm to 1:00pm PDT in Track 2 – Bordeaux. Mr. Goehrum will al

GlobeNewswire last month

BIOYF
BioSyent to Present at LD Micro New York Investor Conference

Mississauga, Ontario--(Newsfile Corp. - April 4, 2025) - BioSyent Inc. (TSXV: RX) ("BioSyent" or the "Company") announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person at the LD Micro Invitational XV Conference in New York City on Thursday, April 10th at 12:00pm EDT. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference on April 10th. These one-on-one meetings can ...

Newsfile last month

BIOYF
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive Year

MISSISSAUGA, Ontario, April 01, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based on a national survey of Canadian pharmacists and physicians(1). This year marks the tenth consecutive year that FeraMAX® has been awarded this vote of confidence from physicians and pharmacists across Canada. We celebrate the consistent ten years of recognition as the top-rated iron supplement with o

GlobeNewswire last month

BIOYF
BioSyent Announces Grant of Restricted Share Units

MISSISSAUGA, Ontario, March 18, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 56,767 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date. About BioSyent Inc. Listed on the TSX

GlobeNewswire last month

BIOYF
BioSyent Full Year 2024 Earnings: Misses Expectations

BioSyent ( CVE:RX ) Full Year 2024 Results Key Financial Results Revenue: CA$35.0m (up 11% from FY 2023). Net income...

Simply Wall St. 2 months ago

BIOYF
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024

MISSISSAUGA, Ontario, March 13, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2024. Key highlights include: (CAD)Q4 2024 % Change vs. Q4 2023 FY 2024 % Change vs. FY 2023 Canadian Pharma Sales8,546,451 +7%32,931,149 +11% International Pharma Sales176,734 +223%929,975 -11%Legacy Business Sales73,499 -68%1,169,773 +18%Total Company Sales8,796,684 +6%35,030,897 +11%EBITDA12,

GlobeNewswire 2 months ago

BIOYF
BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025

MISSISSAUGA, Ontario, March 06, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2024 on Thursday, March 13, 2025 after market hours. A presentation on the Company’s fourth quarter and full year 2024 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture

GlobeNewswire 2 months ago

BIOYF
BioSyent Declares First Quarter 2025 Dividend

MISSISSAUGA, Ontario, Jan. 30, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on March 14, 2025, to shareholders of record at the close of business on February 28, 2025. This first quarter 2025 dividend of $0.05 per common share represents an 11.1% increase from the fourth quarter 2024 dividend of $0.045 per common share.

GlobeNewswire 3 months ago

BIOYF
FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- This press release is being disseminated as required by National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in connection with the filing of an early warning report by FAX Capital Corp. (FAX) regarding the disposition of common shares (Shares) of BioSyent Inc. (BioSyent) (TSXV:RX) through the facilities of the TSX Venture Exchange. FAX announces that, on January 6, 2025, it disposed of 122,910 Sha

GlobeNewswire 4 months ago

BIOYF
BioSyent Announces Renewal of Normal Course Issuer Bid

MISSISSAUGA, Ontario, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 690,000 of its common shares (“Shares”) over a 12-month period, representing approximately 6.07% of the Shares outstanding as of December 13, 2024. The NCIB will commence on De

GlobeNewswire 4 months ago

BIOYF
Investing in BioSyent (CVE:RX) five years ago would have delivered you a 110% gain

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Simply Wall St. 4 months ago

BIOYF
BioSyent Inc. (CVE:RX) Will Pay A CA$0.045 Dividend In Four Days

BioSyent Inc. ( CVE:RX ) stock is about to trade ex-dividend in four days. The ex-dividend date is usually set to be...

Simply Wall St. 5 months ago

BIOYF
BioSyent (CVE:RX) Has Announced A Dividend Of CA$0.045

BioSyent Inc. ( CVE:RX ) will pay a dividend of CA$0.045 on the 16th of December. Including this payment, the dividend...

Simply Wall St. 5 months ago

BIOYF
Calculating The Fair Value Of BioSyent Inc. (CVE:RX)

Key Insights BioSyent's estimated fair value is CA$11.78 based on 2 Stage Free Cash Flow to Equity With CA$11.20 share...

Simply Wall St. 5 months ago

BIOYF

Performance Overview

Return	RX.V	S&P/TSX Composite index (^GSPTSE)
YTD	+3.99%	+5.49%
1-Year	+40.68%	+16.47%
3-Year	+41.84%	+28.53%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioSyent Inc. (RX.V)

BioSyent Releases Financial Results for First Quarter 2025

BioSyent Declares Second Quarter 2025 Dividend

Here's Why We Think BioSyent (CVE:RX) Is Well Worth Watching

BioSyent Schedules First Quarter Earnings Release for May 15, 2025

BioSyent to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference

Could The Market Be Wrong About BioSyent Inc. (CVE:RX) Given Its Attractive Financial Prospects?

BioSyent to Attend Planet MicroCap Showcase

BioSyent to Present at LD Micro New York Investor Conference

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive Year

BioSyent Announces Grant of Restricted Share Units

BioSyent Full Year 2024 Earnings: Misses Expectations

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024

BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025

BioSyent Declares First Quarter 2025 Dividend

FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.

BioSyent Announces Renewal of Normal Course Issuer Bid

Investing in BioSyent (CVE:RX) five years ago would have delivered you a 110% gain

BioSyent Inc. (CVE:RX) Will Pay A CA$0.045 Dividend In Four Days

BioSyent (CVE:RX) Has Announced A Dividend Of CA$0.045

Calculating The Fair Value Of BioSyent Inc. (CVE:RX)

Performance Overview